Detoxification from methadone using low, repeated, and increasing doses of ibogaine: A case report

Opioid misuse, including misuse of prescription opioids such as methadone, has risen sharply in recent years and contributes substantially to overdose mortality and morbidity in Europe and North America. Conventional strategies endorsed by the World Health Organization are gradual dose reduction or opioid substitution treatment (OST) with methadone or buprenorphine; OST reduces harms but often becomes long-term and is associated with persistent medical, cognitive, and quality-of-life problems for some patients. Ibogaine, an alkaloid from Tabernanthe iboga, has shown anti-withdrawal effects in animal models and long-standing anecdotal and case-series evidence in humans, but safety concerns (notably bradycardia and QTc prolongation) and a lack of controlled clinical trials limit its acceptance. Typical therapeutic regimens have used single high doses (around 15–20 mg/kg), and fatalities related to cardiac arrhythmia and comorbid factors have been reported. A recent noribogaine trial in people switched from methadone to morphine showed no reduction in withdrawal at the doses tested and raised the possibility that repeated dosing or different dosing regimens might be required. This report describes a single-case attempt to detoxify a long-term methadone patient using a protocol of low, repeated, and progressively increasing oral doses of ibogaine administered intermittently while methadone doses were reduced. The authors present clinical procedures, monitoring, adverse effects, and follow-up up to 12 months, with the aim of exploring whether a lower-dose, cumulative ibogaine strategy might reduce withdrawal symptoms and methadone dependence while improving safety compared with single high-dose approaches.

This paper is a case report of a 47-year-old woman (58 kg) who had been on methadone maintenance treatment (MMT) for 17 years following past heroin dependence. At the time of the intervention she was stabilised on 37 mg methadone daily and reported occasional intranasal heroin and amphetamine use, daily cannabis, and a history of hepatitis C virus (HCV) infection. Baseline laboratory screening covered >70 parameters including full blood count, biochemistry, hormones, coagulation and serology; abnormalities were minor and without clinical significance. Baseline electrocardiogram (EKG) gave QTc 425 ms, blood pressure 120/70 mm Hg and heart rate 85 bpm. A structured psychiatric interview (M.I.N.I.) produced no psychiatric diagnosis. Outcome and safety measures included the Opiate Withdrawal Scale (OWS) administered daily, the Short OWS (SOWS) before and serially after each ibogaine session, the Brief Psychiatric Rating Scale (BPRS) before and serially after sessions and every morning during treatment, and the Udvalg for Kliniske Undersogelser Side Effects Rating Scale (UKU-SERS) for 24 hours post-session. Physiological monitoring comprised blood pressure and heart rate every 30 min for the first 4 hr, then hourly to 16 hr and at 18 and 24 hr; EKG and QTc measurement were recorded every 60 min for the first 8 hr and at later prespecified time points up to 24 hr. Psychological support was provided throughout and psychotherapy continued for 3 months post-treatment. Treatment was conducted remotely: the patient coordinated with the ICEERS Support Service and clinicians from Pangea Biomedics (a Mexican clinic experienced in ibogaine treatments). Financial constraints prevented travel, so the first four ibogaine sessions had medical supervision but the overall process was overseen live via Skype with local monitoring in Spain. Pharmaceutical-grade ibogaine hydrochloride (96.3% purity by chromatographic and spectrometric analysis) was donated and used orally in a regimen of low, increasing doses (five administrations in total) alternated with progressively reduced methadone doses. The protocol began with a 150 mg dose taken when withdrawal became physiologically evident (OWS 23; SOWS 9). Subsequent exposures were 300, 400, 500 and 600 mg, with methadone often halved between sessions (for example from 37 to 18 mg then stopped). Inter-dose intervals varied from 3 to 7 days according to the patient’s schedule. An EKG machine with QTc readout was used for cardiac monitoring throughout the sessions. The authors report that the first four sessions had direct medical supervision; later sessions were supervised remotely.

Each ibogaine administration produced attenuation or temporary elimination of methadone withdrawal symptoms. With the initial 150 mg dose the patient’s SOWS fell from 9 to 0 within 1 hr, but withdrawal symptoms reappeared approximately 21 hr later (OWS 24). Repeating the pattern with higher incremental doses (300, 400, 500 and finally 600 mg) while reducing methadone ultimately led to the cessation of abstinence syndrome (AS) after the 600 mg dose; the AS did not return thereafter. The extracted text does not give a full time series for the 600 mg dose but reports sustained resolution of withdrawal at the end of the treatment. Lower doses reportedly lacked visual/psychedelic effects but were associated with surfacing of repressed memories and emotions without distressing psychiatric reactions. Safety monitoring recorded a fall in heart rate during the 400 and 500 mg doses, from 85 to 53 bpm within 2–3 hr; sitting or standing increased the heart rate. QTc prolongation did not reach clinically significant thresholds at any time; the highest recorded QTc was 444 ms at 3 hr after the 500 mg dose. On the UKU side-effect scale (severity 1–3) fatigability, memory impairment, akathisia and orthostatic dizziness were rated 1; constipation and tension headache were rated 2; reduction in sleep duration was rated 3; other assessed side effects were rated 0 and no clear dose–response for side effects was reported. The BPRS showed no psychiatric adverse effects. The patient used diazepam 2 mg after the first session to aid sleep and later took orally administered cannabis oil; following recovery from the final session she discontinued methadone, benzodiazepines and cannabis oil. On follow-up, 12 months after the intervention the patient remained off MMT and reported no symptoms of post-acute withdrawal syndrome (PAWS), reduced frequency of other drug use and improvements in life functioning (resuming study, music and volunteering). A laboratory panel performed 7 months post-treatment showed all parameters within reference intervals, although exact post-treatment HCV viral load was not reported in the extracted text.

The authors frame this as the first reported application of a protocol using low, multiple, ascending doses of ibogaine given intermittently between decreasing methadone doses for research and clinical outcome purposes. They suggest this strategy may offer a more rapid alternative to conventional methadone detoxification, which is often prolonged and associated with protracted PAWS, and argue that ibogaine—in contrast to α2-adrenergic agents that reduce but do not eliminate withdrawal—appears capable of significantly reducing or removing abstinence symptoms in this case. Safety considerations are emphasised: even low ibogaine doses can prolong QTc and cause bradycardia, which can be life-threatening. The authors therefore insist that any low-dose protocol must be medically supervised with cardiac monitoring. They also note confusion in the literature because reports often do not distinguish methadone-dependent from heroin-dependent patients, complicating interpretation of prior failures. Mechanistic discussion centres on the complex pharmacology of ibogaine and its principal metabolite noribogaine, which interact with multiple receptors including μ and κ opioid sites and can increase brain-derived neurotrophic factor. The authors hypothesise that repeated dosing may allow accumulation of noribogaine to levels needed to reverse tolerance in long-half-life opioid dependence, whereas a single large dose may be insufficient in the presence of methadone’s prolonged elimination. They contrast this case with a noribogaine trial that failed to reduce withdrawal, suggesting differences in neuropharmacology, dose, or the need for both ibogaine and noribogaine effects acting together. Practical implications discussed include alternating ibogaine with short methadone intervals to improve tolerability, and the possible adjunctive role of benzodiazepines or cannabis for insomnia or stimulant side effects. The authors call for controlled clinical trials comparing single versus multiple dosing regimens to establish safety and efficacy and acknowledge that the mechanisms remain incompletely understood and that cardiac risks and literature heterogeneity represent key limitations of current evidence.